Background and Purpose: In vitro evidence gathered from extracerebral conductance vessels suggests
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in VSM to such a low level that subsequent elevation by a PDE inhibitor was insufficient to relax the aorta.
Since "EDRF" and cGMP are important regulators of cerebrovascular tone,3-5 it was of interest to attempt to replicate the findings of Martin et all using cerebral blood vessels. Moreover, we thought it especially worthwhile to attempt this using an in vivo system and resistance vessels, rather than an in vitro system employing a conductance vessel as was the case in the studies of Martin et al. 1 We employed a well-studied method for injuring endothelium, and we also used inhibitors of "EDRF"-dependent responses.
Materials and Methods The methods have been described in detail many times. [3] [4] [5] [6] [7] [8] Briefly, male mice (ICR strain, Harlan Sprague Dawley, Inc., Indianapolis, Ind.) were anesthetized with urethane. A tracheostomy and craniotomy were performed. The dura was stripped, exposing the transparent arachnoid and the underlying vessels on the brain surface (pial vessels). The mice were maintained at 37°C. The craniotomy site was continuously suffused with Elliott's solution9 at pH 7.3-7.4. All drugs were given in this solution at a final pH that was the same as the pH of the regular suffusate. Diameters were moni-tored via a television microscope and an image-splitting device. Image-splitting techniques permit measurements of less than 0.50 gum.'0,1" Only one arteriole was used per mouse. The arteriole was arbitrarily selected from those 25-45 ,um in internal diameter. Changes in diameter were expressed as a percent of baseline.
To injure the endothelium, a light/dye technique was employed that uses a HeNe laser and Evans blue injected intravenously.3'4 The dye acts as an energyabsorbing, heat-generating target. The laser beam is focused through the objective of the microscope3 and was 36 ,um in diameter. We have published many papers that used this technique to demonstrate endotheliumdependent responses. 3, 4, 7, 12, 13 Drugs Used N-Guanidino-L-monomethyl arginine (L-NMMA) was obtained from Sigma Chemical Co., St. Louis, Mo. This drug inhibits "EDRF"-dependent responses either by inhibiting the enzyme synthesizing "EDRF'14 or by initiating a sequence of events that inactivate "EDRF."7 Stock solutions were made in deionized water and further diluted in Elliott's solution. Inhibitors of PDE were obtained from the sources indicated below. The selectivity shown pertains to the doses we used and is based on the literature that describes the selective action of these inhibitors on either the PDE for cGMP or the PDE for adenosine 3',5'-cyclic monophosphate (cAMP). There is no literature dealing with their selectivities in cerebral blood vessels. Therefore, we used the literature dealing with other test objects. By selecting these doses, which are low and produce small dilations, we minimize the chance that the inhibitors are working via some other, alternative, pathway. 2-o-Propoxyphenyl-8-azapurin-6-one (M+B 22948), an inhibitor of PDE with a selective action on cGMP,15 was a gift from the manufacturer (May and Baker, Dangeham, UK). The following inhibitors were obtained from Research Biochemicals Inc., Natick, Mass.: dipyridamole, which at the dose used is a selective inhibitor of the PDEs with a predominant action against cGMP15; isobutylmethylxanthine (IBMX), which inhibits both the PDE directed against cGMP and the PDE directed against cAMP15; and 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (Ro-201724), which inhibits the PDE directed against cAMP.'5 Stock solutions of the PDE inhibitors were made in ethanol. Subsequent dilutions were made in Elliott's solution. The final concentration of the vehicle in Elliott's solution never exceeded 0.01%. This concentration of ethanol has no effect on our preparations.
Experimental Design
Only one PDE inhibitor was tested per mouse. There were 10 mice in each group, each mouse serving as its own control. The doses selected and the durations of exposure were determined by tests of dose responses and by determining which doses and/or durations produced relaxations that recovered during 5 minutes of washout. Dipyridamole was given for 2 minutes and the other PDE inhibitors for 1 minute. In the laser/dye studies the PDE inhibitor was given 5 minutes before and 10 minutes after injuring the endothelium. A third challenge with the drug was made 15 minutes later, but the diameter change was monitored at a site 100 ,tm away from the site monitored during the first two challenges. The response at the distant site established that inhibition of the response at the site of endothelial injury by laser/dye treatment was not merely due to fatigue of the preparation. The distant site responded in every case. To simplify presentation of the results, these data from the distant site are not given.
When L-NMMA was used, a concentration of 10`6 M was suffused for 10 minutes. It did not produce a change in diameter. To simplify presentation of the results, these negative data are not given, but a similar result was previously reported. 4 The response to a PDE inhibitor with no L-NMMA treatment was compared with the response to a PDE inhibitor with L-NMMA treatment. For each PDE inhibitor, 10 mice were tested, first without and then with L-NMMA. Ten additional mice were first tested after treatment with L-NMMA and again 15 minutes after washout of the L-NMMA. Results were always the same whether the L-NMMAtreated response occurred first or last. Therefore, the data are always combined so n=20 in each study.
Statistics
Since each arteriole served as its own control and the data were expressed as percent change in diameter, the responses before and after treatment were compared using the Wilcoxon matched pairs test.'6 A treatment effect was considered significant when the null hypothesis was rejected at the 0.05 level.
Results
Each PDE inhibitor dilated pial arterioles immediately and in a dose-dependent manner. However, the higher the dose the longer it took for recovery to occur. Doses higher than those shown here might produce larger relaxations but with recovery periods too long for repeated study of the same preparation. Consequently, experiments studying the responses before and after a treatment used low, single doses of PDE inhibitor with a predictably small response. In the case of dipyridamole, only one tested dose gave relaxations that recovered in 5 minutes. This dose was 10`M given for 2 minutes. The other PDE inhibitors produced doserelated, readily reversible dilations when given for 1 minute at doses between 10-6 and 10-8 M (Table 1) . The responses to the low dose of each drug in Table 1 were small, and there were only three mice in each group.
However, the responses to the low dose of each inhibitor proved reliable, as shown when the same low doses were tested in later groups of mice. This is shown in Table 2 , where mean response to the drug is slightly greater than in earlier tests of the same dose shown in Table 1 .
Endothelial damage blocked dilation by three of the PDE inhibitors ( later at a noninjured site, a reversible relaxation was produced. In short, the dilating action of the selective inhibitor of cAMP PDE was apparently less impaired than that of the other PDE inhibitors by endothelial injury. However, irreversible relaxation is difficult to interpret since it may represent some strange interaction of the drug with the injured endothelium. Consequently, the next set of experiments was performed. These used L-NMMA instead of injury to interfere with "EDRF"-dependent phenomena.
L-NMMA at 10-6 M did not alter the diameter of pial arterioles, but it did inhibit the dilation produced by M+B 22948, a selective cGMP PDE inhibitor, and the dilation produced by Ro-201724, the selective cAMP PDE inhibitor (Table 3) . N-Guanidino-D-monomethyl arginine at 10-6 M had no effect (data not shown).
Discussion
The new data in this report demonstrate two important findings: 1) brain arterioles in vivo are dilated by inhibitors selective for either cGMP PDE or cAMP PDE, and 2) this dilation was inhibited by endothelial injury or by L-NMMA.
With respect to our methods, the laser/dye technique as used here on mouse pial arterioles has no effect on a variety of agonists, both dilators and constrictors. This is true for sodium nitroprusside,3'4 cAMP analogue,'7 prostacyclin,7 and uridine triphosphate.13 Consequently, we are confident that the elimination of responses to the PDE inhibitors in the present study was caused by injury to the endothelium and not to VSM. Moreover, L-NMMA in the present animal model and at the concentration used here fails to affect dilation by either bradykinin or prostacyclin.47 Thus, the action of L-NMMA is not due to some action on VSM and is, in fact, selective only for the "EDRF" for acetylcholine and not for the "EDRF" for bradykinin, which appears to be an oxygen-centered free radical in the pial circulation. 18 We used a low concentration of L-NMMA that had no effect on pial arteriole diameter. Higher concentrations cause constriction,4 as would be expected if "EDRF" levels are reduced by L-NMMA. We used the lower dose because this avoids the problems of data interpretation that are introduced when an inhibiting drug also changes basal tone or diameter. The VSM. When a PDE inhibitor was added, the consequent increase of cyclic nucleotide concentrations was insufficient to produce relaxation because the increase was superimposed on a low basal level of cGMP. The fact that dilation by all classes of PDE inhibitor was inhibited in these studies indicates that basal "EDRF" levels and the resulting basal cGMP levels in VSM are necessary not only for normal relaxation by subsequent elevations of the cGMP level but also for normal relaxation by subsequent elevations of the cAMP level. This can be explained by data indicating an additive or synergistic effect on tone by cGMP and cAMP.19,20 While L-NMMA blocked dilation by Ro-201724, a selective inhibitor of cAMP PDE, endothelial injury was far less effective as an inhibitor of that dilation. We cannot explain this discrepancy. However, the postinjury response to Ro-201724 was not reversible, making its interpretation extremely difficult. We do not feel that this peculiar result should negate the conclusion that fits the rest of the data, namely, that when either cGMP or cAMP levels in VSM are elevated, an expected relaxation may not occur if basal levels of cGMP have been reduced by reductions in "EDRF" concentrations resulting from endothelial injury or L-NMMA.
We cannot explain why Martin et al' failed to impair dilation with isoproterenol when they removed aortic endothelium. Presumably isoproterenol is cAMP-dependent, and our new data indicate that responses to cAMP are also impaired if basal cGMP levels are reduced. Perhaps Martin et al' produced much greater increases in the cAMP concentration than were produced in our study. A larger increase in the cAMP level might produce relaxation even with a decrease in the background cGMP level. analogue of cAMP. We would then predict that the same injury would selectively impair inhibitors of cGMP PDE. But the present data show that both PDE inhibitors are impaired by endothelial injury or by interfering with "EDRF." Consequently, our original hypothesis of a role for cGMP in the endothelial synthesis/release of "EDRF" is not supported. To explain our earlier data17 we can only speculate that in the latter experiments equimolar concentrations of cGMP and cAMP analogues produced different increases in levels of these respective nucleotides within VSM. We must suggest that a greater rise in the cAMP concentration was produced and that this rise produced by the cAMP analogue exceeded that produced by any of the PDE inhibitors used in the present experiments. Then the rise in the cAMP level produced in the earlier study was sufficient to produce relaxation in spite of endothelial injury and a fall in basal cGMP levels in VSM while the rise in the cAMP level produced by the PDE inhibitors in the present study was insufficient to produce relaxation in the absence of normal basal levels of cGMP. This reconciliation of the past and present data seems reasonable but must, of course, be considered tentative since levels of nucleotides within the microvascular VSM were not measured in either study.
In any case, the present data demonstrate in vivo in resistance vessels of the brain that endothelial damage and L-NMMA treatment impair the regulation of tone by cyclic nucleotides. This impairment is presumably based on a reduction in basal levels of "EDRF" within VSM.
Editorial Comment
Cyclic nucleotide phosphodiesterases appear to modulate many physiological responses in various cell types and tissues, including platelet aggregation and vascular relaxation.1-3 Phosphodiesterase inhibitors elevate cyclic nucleotide levels by preventing phosphodiesterase from cleaving the specific nucleotide. Thus, the selective use of phosphodiesterase inhibitors can provide valuable insights into investigating the role of phosphodiesterase in physiological responses.
The present studies by Rosenblum et al examine in vivo responses of cerebral (pial) arterioles in mice to topical application of phosphodiesterase inhibitors. In addition, Rosenblum et al examined the role of the endothelium, and endothelium-derived relaxing factor, in dilatation of pial arterioles to application of phosphodiesterase inhibitors. The authors found that phosphodiesterase inhibitors, which produced elevations in the levels of cAMP and cGMP, produced modest dilatation of pial arterioles. More importantly, dilatation of pial arterioles in response to phosphodiesterase inhibition could be attenuated by injury to the endothelium or by application of an enzymatic inhibitor of nitric oxide, L-NMMA. Thus, the present studies by Rosenblum 
